Latest Market Challenges News

Origin Energy’s June 2025 quarterly report reveals a slight dip in LNG revenue due to softer prices, steady production, and robust customer expansion across its retail and international businesses.

Galan Lithium has locked in a $20 million strategic placement and secured a key Argentine government incentive, positioning its Hombre Muerto West project for production in early 2026.

Dubber Corporation Limited has achieved underlying operating cashflow breakeven for the first time in its history in Q4 FY25, despite the looming impact of a major contract non-renewal. The company plans to offset margin losses through aggressive cost savings and revenue growth in FY26.

Rio Tinto reported robust half-year results with $11.5 billion underlying EBITDA, advancing key projects and completing a major lithium acquisition amid challenging market conditions.

Volt Resources reports robust progress on its Alabama Graphite Refinery scoping study, strategic partnerships in Tanzania, and resilient production in Ukraine, positioning itself strongly amid evolving graphite market dynamics.

TZ Limited has landed a significant bulk order from Microsoft and completed the Keyvision acquisition, positioning itself for a strong FY26 despite recent US market challenges.

Appen Limited reported a mixed Q2 FY25 with a 6% revenue decline year-over-year, driven by a strong 77% surge in its China business that achieved profitability, while US market challenges persist. The company targets $10 million in cost savings to fuel future growth.

Pilbara Minerals delivered a standout June quarter with record spodumene production and robust financials, beating FY25 guidance and setting ambitious targets for FY26 amid ongoing market challenges.

Nova Eye Medical has reported a record A$29.2 million revenue for FY25, driven by strong sales growth and improved profitability in its glaucoma segment. The company targets breakeven EBITDA in the first half of FY26 alongside continued cash flow improvements.

Liontown Resources reported robust FY25 results with over 294,000 dmt of spodumene concentrate produced and commenced underground mining on schedule. The company is transitioning to 100% underground production by Q3 FY26, aiming for scalable, low-cost operations from FY27 despite a 36% drop in spodumene prices.

Acrow Limited confirms FY25 financial guidance with solid sales and EBITDA growth, while securing a significant seven-year contract extension with Origin Energy that bolsters its Industrial Access division outlook for FY26.

Nova Eye Medical has reported a record A$29.2 million revenue for FY25, driven by strong sales growth and improved profitability in its glaucoma segment. The company targets breakeven EBITDA in the first half of FY26 amid promising regulatory and market developments.